Regeneron Pharmaceuticals Current Ratio 2006-2021 | REGN

Current and historical current ratio for Regeneron Pharmaceuticals (REGN) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Regeneron Pharmaceuticals current ratio for the three months ending June 30, 2021 was 3.57.
Regeneron Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $13.34B $3.73B 3.57
2021-03-31 $10.06B $3.22B 3.13
2020-12-31 $9.78B $2.70B 3.63
2020-09-30 $9.10B $2.34B 3.89
2020-06-30 $7.86B $3.70B 2.12
2020-03-31 $8.64B $2.06B 4.21
2019-12-31 $7.69B $2.10B 3.67
2019-09-30 $7.11B $1.77B 4.03
2019-06-30 $6.65B $1.71B 3.88
2019-03-31 $6.93B $1.51B 4.58
2018-12-31 $6.45B $1.44B 4.47
2018-09-30 $5.72B $1.42B 4.04
2018-06-30 $4.82B $1.33B 3.62
2018-03-31 $4.55B $1.27B 3.59
2017-12-31 $4.34B $1.14B 3.82
2017-09-30 $4.14B $1.14B 3.63
2017-06-30 $3.86B $1.03B 3.75
2017-03-31 $3.67B $1.31B 2.81
2016-12-31 $3.18B $1.24B 2.56
2016-09-30 $3.50B $0.96B 3.64
2016-06-30 $3.21B $0.95B 3.37
2016-03-31 $3.13B $0.92B 3.41
2015-12-31 $2.92B $0.81B 3.59
2015-09-30 $2.68B $0.74B 3.64
2015-06-30 $2.28B $0.60B 3.80
2015-03-31 $2.31B $0.54B 4.31
2014-12-31 $2.09B $0.66B 3.18
2014-09-30 $2.20B $0.41B 5.36
2014-06-30 $1.92B $0.35B 5.46
2014-03-31 $1.87B $0.31B 6.13
2013-12-31 $1.80B $0.30B 6.01
2013-09-30 $1.63B $0.27B 6.08
2013-06-30 $1.56B $0.20B 7.66
2013-03-31 $1.31B $0.20B 6.63
2012-12-31 $1.21B $0.16B 7.37
2012-09-30 $0.95B $0.18B 5.31
2012-06-30 $0.77B $0.18B 4.20
2012-03-31 $0.70B $0.16B 4.35
2011-12-31 $0.67B $0.15B 4.49
2011-09-30 $0.34B $0.13B 2.55
2011-06-30 $0.41B $0.14B 3.04
2011-03-31 $0.33B $0.11B 2.90
2010-12-31 $0.36B $0.11B 3.28
2010-09-30 $0.58B $0.13B 4.30
2010-06-30 $0.42B $0.12B 3.49
2010-03-31 $0.40B $0.10B 3.80
2009-12-31 $0.43B $0.09B 4.55
2009-09-30 $0.46B $0.11B 4.04
2009-06-30 $0.47B $0.12B 3.86
2009-03-31 $0.48B $0.10B 4.69
2008-12-31 $0.52B $0.08B 6.23
2008-09-30 $0.72B $0.22B 3.29
2008-06-30 $0.74B $0.22B 3.32
2008-03-31 $0.79B $0.29B 2.75
2007-12-31 $0.80B $0.28B 2.81
2007-09-30 $0.42B $0.10B 4.37
2007-06-30 $0.50B $0.11B 4.74
2007-03-31 $0.49B $0.08B 5.85
2006-12-31 $0.47B $0.05B 10.44
2006-09-30 $0.27B $0.03B 8.37
2006-06-30 $0.29B $0.03B 9.24
2006-03-31 $0.32B $0.03B 9.49
2005-12-31 $0.34B $0.04B 8.46
2005-09-30 $0.33B $0.03B 9.69
2005-06-30 $0.36B $0.03B 12.00
2005-03-31 $0.37B $0.03B 12.36
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $61.217B $8.497B
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76